Geïndividualiseerde cryoneurolyse voor de behandeling van pijn in de context van spasticiteit in de bovenste en onderste ledematen (ICE)
Geïndividualiseerde Cryoneurolyse voor Pijnbehandeling in de Context van Spasticiteit in de Bovenste en Onderste Extremiteiten (ICE): een Pilot Gerandomiseerd Gecontroleerd Onderzoek
Spasticity is an umbrella term for impairments of muscle tone and control in people with damage to the brain and spinal cord. It is highly prevalent and results in pain, stiffness, and contribute to difficulties in activities of daily living. Current treatment options are limited, and many people experience only partial reduction in spasticity and frequent repeated treatments are needed.
Cryoneurolysis is a medical technique which involves the controlled freezing of the nerves. It has been approved in the UK for the treatment of pain in the context of spasticity through the targeting of nerves which control problematic muscles. Oxford University Hospitals NHS Foundation Trust has been offering this treatment routinely since January 2024. This pilot study aims to improve the understanding of the potential effectiveness of this treatment and its potential side effects when compared with a more commonly used treatment (Botulinum Toxin).
Participants will be randomly allocated to receive usual care with Botulinum Toxin (control group) or usual care with Cryoneurolysis (intervention group). The investigators will assess pain, goal attainment, side effects, spasticity, disability and independence in daily activities, and movement of the arm and leg. Assessments will be at baseline and then 6-, 12-, 18-, and 24-weeks following treatment. Participants who are randomised to the control group will have the opportunity to receive cryoneurolysis treatment after the 12 week follow up assessment.
The results of this study will help to guide future studies to examine the effectiveness of this treatment.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Spasticity is an umbrella term for impairments of muscle activity and control in the context of damage or dysfunction in the central nervous system, occurring in up to 87% of spinal cord injury patients, 42% of stroke patients, and 80% of patients with multiple sclerosis. Spasticity results in pain, stiffness, and restrictions to activity including difficulties in personal care and mobility and a significant impact on quality of life.
Treatments including oral medications, botulinum toxin injections, and physical therapies can provide some degree of relief, but effectiveness varies widely. Many patients experience only partial reduction in spasticity, contributing to ongoing functional limitations. Botulinum toxin injections provide temporary relief necessitating frequent treatments (every 3-4 months). This is burdensome for patients and healthcare providers, with associated time and treatment costs. Pharmacological treatments can lead to systemic side effects including drowsiness, dizziness, and cognitive impairments. Surgical interventions are resource-intensive and require specialised medical facilities. Their associated costs, in terms of financial resources and healthcare infrastructure, significantly limit access for certain patients.
Cryoneurolysis, a novel medical technique, involves the controlled freezing of nerve tissue to temporarily disrupt its function. While primarily used for pain, there is a growing interest in its application for managing spasticity and it is currently approved for the treatment of pain in the context of spasticity at Oxford University Hospitals NHS Trust. Observational studies suggest immediate relaxation of the affected muscles, resulting in improved joint range of motion, enhanced functional mobility, and reduced pain. The investigators' own open-label proof-of-principle clinical data suggest the potential for substantial improvements in the impact of spasticity on quality of life.
This pilot randomised controlled study aims to improve the understanding of the potential clinical effectiveness and side effect profile of cryoneurolysis as a treatment for pain in the context of spasticity in people with a range of neurological conditions (e.g. acquired brain injury (ABI), spinal cord injury, stroke, multiple sclerosis).
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Anton Pick, MBChB
- Telefoonnummer: (+44) 01865 737306
- E-mail: anton.pick@ouh.nhs.uk
Studie Contact Back-up
- Naam: Barbara Robinson, MSc
- E-mail: barbara.robinson@ndcn.ox.ac.uk
Studie Locaties
-
-
-
Oxford, Verenigd Koninkrijk, OX3 7HE
- Werving
- Oxford Centre for Enablement (OUH NHS-FT)
-
Contact:
- Anton Pick, MBChB
- Telefoonnummer: +44 01865 737 306
- E-mail: anton.pick@ouh.nhs.uk
-
Hoofdonderzoeker:
- Anton Pick, MBChB
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial OR a positive opinion from a consultee is provided by a family member or carer (relative or friend) willing to provide personal consultee (PC) advice.
- Male or Female, aged 18 years or above.
- Diagnosed with a central neurological condition, including acquired brain injury (e.g. from ischaemic stroke, trauma, or haemorrhage), multiple sclerosis, and spinal cord injury.
- Clinical indication for Botulinum Toxin and Cryoneurolysis treatment, including pain associated with spasticity and with a clinically meaningful response to diagnostic nerve block to specific nerves or nerve branches that can be treated with cryoneurolysis.
- At least one rehabilitation goal related to management of pain resulting from spasticity.
Exclusion Criteria:
- Participant has received Botulinum toxin or cryoneurolysis within the last 90 days.
- Raynaud's syndrome.
- Cryoglobulinaemia.
- Cold urticaria.
- Bleeding disorders.
- Localised infection at intended treatment site.
- Planned oral antispasmodic medication dose changes.
- Pregnancy, breastfeeding, or planning pregnancy in the trial period.
- Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
- Participants who are currently enrolled in another trial may be excluded if it is deemed (in the investigator's opinion) that participation could influence the results for either study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cryoneurolyse (+ gebruikelijke zorg)
|
Nerves that require treatment, and the number of treatments required for each nerve will be identified by routine clinical judgement. Nerve targets are identified using an ultrasound machine. The handheld Iovera cryoneurolysis device will be used for treatment. Participants will receive up to 4 treatments of cryoneurolysis for each nerve or nerve branch that requires treatment. It is anticipated that participants will have between 1 and 5 nerves or nerve branches per limb treated. Each Cryoneurolysis treatment takes 110 seconds. Total treatment time will be determined by number of nerves targeted and number of cryoneurolysis treatments per nerve. The shortest duration, with setup, is likely to be 60 minutes and the longest 120 minutes.
Andere namen:
|
|
Actieve vergelijker: Botulinum Toxine (+ gebruikelijke zorg)
|
Muscles that require treatment with Botulinum Toxin will be identified by routine clinical assessment. Muscle targets will be identified using an ultrasound machine. It is anticipated that participants will have between 2 and 8 muscles identified for target. The participant will receive up to 200 units of Xeomin (Botulinum Toxin) per muscle that requires treatment. Treatment session of Botulinum Toxin will take 60 to 90 minutes.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Goal Attainment Scale
Tijdsspanne: 6-weeks post-treatment
|
An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected). |
6-weeks post-treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Self-reported Pain
Tijdsspanne: 6, 12, 18, and 24 weeks post-treatment
|
Self-report, as measured by a numerical rating scale (range 0 - 10, higher scores indicating higher pain levels). |
6, 12, 18, and 24 weeks post-treatment
|
|
Douleur Neuropathique en 4 (DN4)
Tijdsspanne: 6, 12, 18, and 24 weeks post-treatment
|
Questionnaire used to determine whether pain is neuropathic in origin (range 0 - 10; a score of 4 or more suggests the presence of neuropathic pain). |
6, 12, 18, and 24 weeks post-treatment
|
|
Neuropathic Pain Symptom Inventory (NPSI)
Tijdsspanne: 6, 12, 18, and 24 weeks post-treatment
|
Questionnaire used to quantify neuropathic pain (range 0 - 100, higher scores reflect worse neuropathic pain). |
6, 12, 18, and 24 weeks post-treatment
|
|
Side Effects
Tijdsspanne: 6, 12, 18, and 24 weeks post-treatment
|
As measured by self-report side effects questionnaire |
6, 12, 18, and 24 weeks post-treatment
|
|
Goal Attainment Scale
Tijdsspanne: 12-weeks post treatment
|
An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected). |
12-weeks post treatment
|
|
Modified Ashworth Scale
Tijdsspanne: 6- and 12-weeks post treatment
|
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased in tone). |
6- and 12-weeks post treatment
|
|
Modified Tardieu Scale
Tijdsspanne: 6- and 12-weeks post treatment
|
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased resistance). |
6- and 12-weeks post treatment
|
|
Spasticity
Tijdsspanne: 6- and 12-weeks post treatment
|
Directly assessed by measuring the muscle activity to a passive stretch |
6- and 12-weeks post treatment
|
|
Range of Motion
Tijdsspanne: 6- and 12-weeks post treatment
|
Assessed using a goniometer |
6- and 12-weeks post treatment
|
|
Patient Reported Impact of Spasticity Measure (PRISM)
Tijdsspanne: 6- and 12-weeks post treatment
|
Questionnaire assessing spasticity related quality of life (41 items that describe impacts of spasticity, each of which is rated on a scale of 0-4 from "never true for me" to "very often true for me"). |
6- and 12-weeks post treatment
|
|
EQ5D
Tijdsspanne: 6- and 12-weeks post treatment
|
Questionnaire assessing quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels which are scored 1 - 5, with higher scores indicating worse outcome. |
6- and 12-weeks post treatment
|
|
Spasticity Related Quality of Life instrument (SQoL-6D)
Tijdsspanne: 6- and 12-weeks post treatment
|
Questionnaire assessing spasticity related quality of life (range 0 - 24, higher score indicating worse condition) |
6- and 12-weeks post treatment
|
|
Barthel Index
Tijdsspanne: 6- and 12-weeks post treatment
|
Scale measuring a person's ability to complete activities of daily living (range 0 - 100, higher scores indicating more independence) |
6- and 12-weeks post treatment
|
|
Gait assessment - Walking Speed
Tijdsspanne: 6- and 12-weeks post treatment
|
Kinematic assessment of lower extremity function, using EMG and motion capture cameras. Walking speed is measured in meters per second (m/s), with slower speed indicating worse outcome. |
6- and 12-weeks post treatment
|
|
Gait assessment - Gait profile score
Tijdsspanne: 6- and 12-weeks post treatment
|
Kinematic assessment of lower extremity function using EMG and motion capture cameras. The gait profile score is measured in degrees, with higher scores indicating more abnormality, and no maximum score. |
6- and 12-weeks post treatment
|
|
Leg Activity Measure (LEG-A)
Tijdsspanne: 6- and 12-weeks post treatment
|
Questionnaire assessing lower extremity function (3 sections: Section A range: 0-36; Section B range 0-60; Section C range 0 - 36. Higher score indicates more difficulty/severity.) |
6- and 12-weeks post treatment
|
|
Shriners Hospital Upper Extremity Evaluation (SHUEE)
Tijdsspanne: 6- and 12-weeks post treatment
|
Kinematic assessment of upper extremity function using motion capture cameras. |
6- and 12-weeks post treatment
|
|
Arm Activity Measure (ARM-A)
Tijdsspanne: 6- and 12-weeks post treatment
|
Questionnaire assessing upper extremity function (2 sections: Section A range: 0-32; Section B range 0-52. Higher score indicates more difficulty.) |
6- and 12-weeks post treatment
|
|
Functional Assessment Test for Upper Limb (FAST-UL)
Tijdsspanne: 6- and 12-weeks post treatment
|
Assessment of upper extremity function (selected movements assessed and scored between 0 - 3, with higher scores indicating ability to complete movement more fully). |
6- and 12-weeks post treatment
|
|
Pressure Pain Thresholds (PPT)
Tijdsspanne: 6, 12, 18, and 24 weeks post-treatment
|
Sensory testing using a manual algometer to assess pain thresholds. |
6, 12, 18, and 24 weeks post-treatment
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Feedback Questionnaire/Interview
Tijdsspanne: 24 weeks post treatment
|
Qualitative feedback using either a semi-structured interview or a self-reported questionnaire (using the same questions as interview schedule), as per preference of participant, used to explore the satisfaction, experience, and anticipated barriers/facilitators to clinical implementation for the treatments. |
24 weeks post treatment
|
|
Sleep Condition Indicator
Tijdsspanne: 6, 12, 18, and 24 weeks post-treatment
|
Questionnaire assessing self-reported insomnia symptoms (range 0-32, higher numbers indicate less symptoms of insomnia) |
6, 12, 18, and 24 weeks post-treatment
|
|
Goal Attainment Scale
Tijdsspanne: 18- and 24-weeks post-treatment
|
An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected). |
18- and 24-weeks post-treatment
|
|
Modified Ashworth Scale
Tijdsspanne: 18- and 24-weeks post-treatment
|
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased in tone). |
18- and 24-weeks post-treatment
|
|
Modified Tardieu Scale
Tijdsspanne: 18- and 24-weeks post-treatment
|
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased resistance). |
18- and 24-weeks post-treatment
|
|
Spasticity
Tijdsspanne: 18- and 24-weeks post-treatment
|
Directly assessed by measuring the muscle activity to a passive stretch |
18- and 24-weeks post-treatment
|
|
Range of motion
Tijdsspanne: 18- and 24-weeks post-treatment
|
Assessed using a goniometer |
18- and 24-weeks post-treatment
|
|
Patient Reported Impact of Spasticity Measure (PRISM)
Tijdsspanne: 18- and 24-weeks post-treatment
|
Questionnaire assessing spasticity related quality of life (41 items that describe impacts of spasticity, each of which is rated on a scale of 0-4 from "never true for me" to "very often true for me") |
18- and 24-weeks post-treatment
|
|
EQ5D
Tijdsspanne: 18- and 24-weeks post-treatment
|
Questionnaire assessing quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels which are scored 1 - 5, with higher scores indicating worse outcome. |
18- and 24-weeks post-treatment
|
|
Spasticity Related Quality of Life instrument (SQoL-6D)
Tijdsspanne: 18- and 24-weeks post-treatment
|
Questionnaire assessing spasticity related quality of life (range 0 - 24, higher score indicating worse condition) |
18- and 24-weeks post-treatment
|
|
Barthel Index
Tijdsspanne: 18- and 24-weeks post-treatment
|
Scale measuring a person's ability to complete activities of daily living (range 0 - 100, higher scores indicating more independence) |
18- and 24-weeks post-treatment
|
|
Leg Activity Measure (LEG-A)
Tijdsspanne: 18- and 24-weeks post-treatment
|
Questionnaire assessing lower extremity function (3 sections: Section A range: 0-36; Section B range 0-60; Section C range 0 - 36. Higher score indicates more difficulty/severity.) |
18- and 24-weeks post-treatment
|
|
Arm Activity Measure (ARM-A)
Tijdsspanne: 18- and 24-weeks post-treatment
|
Questionnaire assessing upper extremity function (2 sections: Section A range: 0-32; Section B range 0-52. Higher score indicates more difficulty.) |
18- and 24-weeks post-treatment
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Algemene publicaties
- Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016 Jun;25(3):1057-73. doi: 10.1177/0962280215588241. Epub 2015 Jun 19.
- Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013 Jan 15;80(3 Suppl 2):S13-9. doi: 10.1212/WNL.0b013e3182762448.
- Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004 Oct;10(5):589-95. doi: 10.1191/1352458504ms1085oa.
- Winston P, Mills PB, Reebye R, Vincent D. Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use. Arch Rehabil Res Clin Transl. 2019 Oct 17;1(3-4):100030. doi: 10.1016/j.arrct.2019.100030. eCollection 2019 Dec.
- Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, Ashford S; Upper Limb International Spasticity (ULIS-III) study group. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. J Rehabil Med. 2021 Feb 24;53(2):jrm00157. doi: 10.2340/16501977-2801.
- Skoog B, Jakobsson KE. Prevalence of Spasticity and Below-Level Neuropathic Pain Related to Spinal Cord Injury Level and Damage to the Lower Spinal Segments. J Rehabil Med Clin Commun. 2020 Mar 8;3:1000039. doi: 10.2340/20030711-1000039. eCollection 2020.
- Kim PS, Ferrante FM. Cryoanalgesia: a novel treatment for hip adductor spasticity and obturator neuralgia. Anesthesiology. 1998 Aug;89(2):534-6. doi: 10.1097/00000542-199808000-00036. No abstract available.
- Biel E, Aroke EN, Maye J, Zhang SJ. The applications of cryoneurolysis for acute and chronic pain management. Pain Pract. 2023 Feb;23(2):204-215. doi: 10.1111/papr.13182. Epub 2022 Dec 4.
- Bhimani R, Anderson L. Clinical understanding of spasticity: implications for practice. Rehabil Res Pract. 2014;2014:279175. doi: 10.1155/2014/279175. Epub 2014 Sep 4.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Musculoskeletale aandoeningen
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Spierziekten
- Spier hypertonie
- Neuromusculaire manifestaties
- Wonden en verwondingen
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Demyeliniserende auto-immuunziekten, CZS
- Auto-immuunziekten van het zenuwstelsel
- Demyeliniserende ziekten
- Craniocerebraal trauma
- Trauma, zenuwstelsel
- Ziekten van het ruggenmerg
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Pijn
- Spier spasticiteit
- Hartinfarct
- Multiple sclerose
- Hersenletsel
- Ruggenmergletsels
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Chirurgische procedures, operatief
- Biologische factoren
- Hydrolasen
- Enzymen
- Enzymen en co -enzymen
- Anesthesie en analgesie
- Neurochirurgische procedures
- Metalloendopeptidasen
- Endopeptidasen
- Peptide hydrolasen
- Metalloproteasen
- Bacteriële eiwitten
- Bacteriële gifstoffen
- Gifstoffen, biologisch
- Anesthesie, geleiding
- Anesthesie
- Denervatie
- Botulinetoxinen, type A
- Botulinetoxinen
- incobotulinetoxineA
- Zenuwblokkade
Andere studie-ID-nummers
- PID 18403
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified data are available upon reasonable request.
IPD-tijdsbestek voor delen
Following publication of results
IPD-toegangscriteria voor delen
Available upon reasonable request
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .